To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Government Operations, Transportation.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section S1: 1. Short title This Act may be cited as the Increasing Access to Biosimilars Act of 2023.
- Section HE2C6A38D450A4F038FC5048331903E63: 2. Demonstration project to increase access to biosimilar biological products under the Medicare program Subject to subsection (f), beginning not later than 1...
- Section H71F8A175E3634778ACCBEB47156A10C9: 3. Extending eligibility for certain payment increases for biosimilar biological products under the Medicare program Section 1847A(b)(8)(B)(ii)(II) of the...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Government Operations, Transportation
Primary Purpose
This bill, To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMr. Cornyn (for himself and Mr. Bennet) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology